CPTCF (Cytophage Technologies) Change In Receivables : $-0.38 Mil (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Change In Receivables?

Cytophage Technologies's change in receivables for the quarter that ended in Sep. 2024 was $-0.02 Mil. It means Cytophage Technologies's Accounts Receivable increased by $0.02 Mil from Jun. 2024 to Sep. 2024 .

Cytophage Technologies's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.18 Mil. It means Cytophage Technologies's Accounts Receivable increased by $0.18 Mil from Dec. 2022 to Dec. 2023 .

Cytophage Technologies's Accounts Receivable for the quarter that ended in Sep. 2024 was $0.12 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cytophage Technologies's liquidation value for the three months ended in Sep. 2024 was $0.38 Mil.

Cytophage Technologies Change In Receivables Historical Data

The historical data trend for Cytophage Technologies's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Change In Receivables Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Change In Receivables

-0.02

-0.06

-0.18

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial					-0.01	-0.33	-0.04	0.01	-0.02

Cytophage Technologies Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.38 Mil.

Cytophage Technologies (GREY:CPTCF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cytophage Technologies's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.123	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Cytophage Technologies's accounts receivable are only considered to be worth 75% of book value:

Cytophage Technologies's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1.735	-	1.451	+	0.75 * 0.123	+	0.5 * 0
=	0.38

Cytophage Technologies Change In Receivables Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (GREY:CPTCF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

CYTO:Canada

Address

26 Henlow Bay, Winnipeg, MB, CAN, R3Y 1G4

Website

https://www.cytophage.com

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.